Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Avalo Therapeutics, Inc. (AVTX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M | $5.4M | $6.7M | $6.8M | $7.0M | $27.8M | $1.2M | $0 | — | — |
| Research & development | $50.1M | $24.4M | $13.8M | $31.3M | $59.8M | $32.2M | $11.8M | $5.8M | $4.4M | $10.1M | $6.6M | $12.2M | $8.9M |
| Operating expenses | — | — | — | — | — | — | — | $57.6M | $13.9M | $17.2M | $11.0M | — | — |
| Operating income | −$72.9M | −$68.5M | −$27.4M | −$37.4M | −$82.1M | −$72.8M | −$16.1M | −$35.4M | $13.9M | −$16.1M | −$11.0M | −$17.1M | −$12.9M |
| EBITDAderived | −$72.6M | −$68.3M | −$27.2M | −$37.3M | −$80.5M | −$71.0M | −$12.3M | −$30.8M | $14.3M | −$16.1M | −$11.0M | — | — |
| Net income | −$78.3M | −$35.1M | −$31.5M | −$41.7M | −$84.4M | −$63.5M | −$16.1M | −$40.1M | $11.9M | −$16.5M | −$10.5M | −$16.1M | −$13.0M |
| Basic EPSper diluted share | -$5.84 | -$7.94 | -$113.58 | -$1,063.00 | — | — | — | -$1.20 | $0.42 | -$1.87 | -$4.71 | -$5.48 | -$20.72 |
| Diluted EPSper diluted share | -$5.84 | -$20.91 | -$113.58 | -$1,063.00 | — | — | — | -$1.20 | $0.42 | -$1.87 | -$4.71 | -$5.48 | -$20.72 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Doyle MittieChief Medical Officer | SellCommon Stock | 1.4K | $18.00 | $26.1K | 51.8K |
| May 28, 2026Form 4 · 10b5-1 | Doyle MittieChief Medical Officer | SellCommon Stock | 679 | $16.00 | $10.9K | 47.1K |
| May 15, 2026Form 4 · 10b5-1 | Doyle MittieChief Medical Officer | SellCommon Stock | 3.0K | $18.76 | $56.3K | 3.6K |
| May 7, 2026Form 4 · 10b5-1 | Sullivan Christopher RyanChief Financial Officer | SellCommon Stock | 18.6K | $24.12 | $448.8K | 423 |
| May 6, 2026Form 4 · 10b5-1 | Doyle MittieChief Medical Officer | SellCommon Stock | 10.1K | $22.88 | $230.1K | 3.6K |